In a significant stride towards transforming women’s healthcare, Aspivix, a leading innovator in gynecological solutions, is thrilled to announce that its pioneering device, Carevix™, has received approval from the Medicines & Healthcare products Regulatory Agency (MHRA) for use in the United Kingdom. This milestone marks a pivotal moment for the company and underscores its commitment to modernizing gynecology under its mission, “Gynecology. Now Modern.”
The MHRA approval signifies a major leap forward in the availability of advanced, pain-relieving solutions for millions of women, propelling Aspivix into the forefront of women’s healthcare innovation.
Carevix™ is designed to redefine the standards of care in gynecology, offering a more comfortable and empowering experience for patients and healthcare providers alike for transcervical procedures in gynecology, oncology and fertility, including IUD/coil insertions.
Furthermore, Carevix™ has now received approval from ANVISA for use in Brazil. Aspivix welcomes its 1st site University of Campinas, Cemicamp, in Brazil, running a clinical study aligned with its mission to drive forward innovation in gynecology and offering to thousands of women can access safe contraception in low and middle-income countries as well.
